Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12142383 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| Iotranic Acid SCHEMBL2109613 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| Iodoxamic Acid SCHEMBL29397252 | 1.00 | TSHR (0.74) | TSHRMAPK1LMNACYP1A2CYP3A4 | |
| Iotroxic Acid SCHEMBL27729545 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotetric Acid SCHEMBL37863 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotroxic Acid SCHEMBL38038 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iotetric Acid SCHEMBL27748028 | 0.89 | TSHR (0.65) | TSHRMAPK1LMNANPC1RAB9A | |
| Iodipamide SCHEMBL29606858 | 0.85 | TSHR (1.00) | TSHRMAPK1CYP3A4MEN1KMT2A | |
| Iodipamide SCHEMBL37678 | 0.85 | TSHR (1.00) | TSHRMAPK1CYP3A4MEN1KMT2A | |
| SCHEMBL12143826 | 0.84 | TSHR (0.80) | TSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006073711-A2 | USE OF A MATRIX COMPRISING A CONTRAST AGENT IN SOFT TISSUES | KUROS BIOSURGERY AG (CH) | 2006-07-13 | — | — | WO | claimed |
| US-12350375-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| US-12269790-B1 | Process for the preparation of 2,4,6-triiodophenol derivatives | BRACCO IMAGING S.P.A. (IT) | 2025-04-08 | — | — | US | disclosed |
| US-20250109094-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVES | BRACCO IMAGING S.P.A. (IT) | 2025-04-03 | — | — | US | disclosed |
| CN-119095823-A | Process for preparing 2,4, 6-triiodophenol derivatives | 伯拉考成像股份公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2023209165-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVES | BRACCO IMAGING SPA (IT) | 2023-11-02 | — | — | WO | disclosed |
| US-20220325250-A1 | METHOD FOR OBTAINING EFFICIENT COMPOSITIONS COMPRISING VIRAL VECTORS FOR VACCINATION OR GENE THERAPY | LEUKOCARE AG (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-114929233-A | Phosphodiesterase type V inhibitor compositions, methods of making them, and methods of using them | 美国瑞根特有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220202717-A1 | Novel Method for Obtaining Efficient Viral Vector-Based Compositions for Vaccination or Gene Therapy | LEUKOCARE AG (DE) | 2022-06-30 | — | — | US | disclosed |
| US-11166915-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2021-11-09 | — | — | US | disclosed |
| EP-0968173-A1 | PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENTS AND INTERMEDIATES THEREFOR | NYCOMED IMAGING AS (NO) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999018054-A1 | PROCESS FOR THE CRYSTALLISATION OF STERICALLY HINDERED COMPOUNDS | NYCOMED IMAGING AS (NO) | 1999-04-15 | — | — | WO | disclosed |
| US-5824821-A | EPOXIDATION OF ALLYLAMINO COMPOUND, HYDROLYSIS TO YIELD 2,3-DIHYDROXYPROPYLAMINO COMPOUNDS | NYCOMED IMAGING AS (NO) | 1998-10-20 | — | — | US | disclosed |
| WO-1998034905-A1 | PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENTS AND INTERMEDIATES THEREFOR | NYCOMED IMAGING AS (NO) | 1998-08-13 | — | — | WO | disclosed |
| EP-0828705-A1 | IODINATION PROCESS | NYCOMED IMAGING AS (NO) | 1998-03-18 | — | — | EP | disclosed |
| US-5672335-A | ADMINISTERING TO ENHANCE CONTRAST IN COMPUTER TOMOGRAPHY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-30 | — | — | US | disclosed |
| WO-1996037461-A1 | IODINATION PROCESS | NYCOMED IMAGING A.S (NO) | 1996-11-28 | — | — | WO | disclosed |
| US-5575905-A | Iodination process | NYCOMED IMAGING AS (NO) | 1996-11-19 | — | — | US | disclosed |
| US-5250283-A | Alpha-fluoro-N-trifluoroacetyliopanoic acid; nontoxic choleretic agent for X-ray imaging of the bile ducts | MOLECULAR BIOSYSTEMS, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5143715-A | N-trifluoroacetyliopanoic acid; nontoxic, increased choleretic activity; radiology | MOLECULAR BIOSYSTEMS, INC. (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109094-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVES | TPO, IPO4, CYP4F2 | TSHR 15/4885MAPK1 1171/4885LMNA 4646/4885 |
| US-12269790-B1 | Process for the preparation of 2,4,6-triiodophenol derivatives | TPO, IPO4, CYP4F2 | TSHR 15/4885MAPK1 1171/4885LMNA 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.